Stock Events

Stock Events

PhaseRx 

$0
2
+$0+0% Wednesday 13:30

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
250
Avg. Volume
-
Mkt Cap
1,169
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

10NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
0
0.33
0.67
1
Expected EPS
0
Actual EPS
0

Financials

-Profit Margin
Unprofitable
2014
2015
2016
0Revenue
-40.27MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PZRXQ. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for genetic diseases, directly competing with PhaseRx's RNA-targeted treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals specializes in antisense technology, which is similar to PhaseRx's RNA-based drug development.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap9.12B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, similar to PhaseRx's approach.
Sarepta Therapeutics
SRPT
Mkt Cap2.22B
Sarepta Therapeutics focuses on RNA-targeted drug discovery, particularly in areas like Duchenne muscular dystrophy, a potential area for PhaseRx.
Moderna
MRNA
Mkt Cap20.21B
Moderna Inc. is known for its work in mRNA therapies, which competes with PhaseRx's focus on RNA technologies.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical develops enzyme replacement therapies, which can be seen as alternative treatments to PhaseRx's genetic disorder therapies.
uniQure N.V.
QURE
Mkt Cap961.7M
uniQure is involved in gene therapy for genetic diseases, competing with PhaseRx's gene-focused therapeutic approaches.

About

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.
Show more...
CEO
Dr. Robert W. Overell Ph.D.
Employees
10
Country
United States
ISIN
US71723F1030

Listings

OTC Link
US
PZRXQ

0 Comments

Share your thoughts

FAQ

What is PhaseRx stock price today?▼
The current price of PZRXQ is $0 USD — it has increased by +0% in the past 24 hours. Watch PhaseRx stock price performance more closely on the chart.
What is PhaseRx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PhaseRx stocks are traded under the ticker PZRXQ.
What is PhaseRx market cap?▼
Today PhaseRx has the market capitalization of 1,169
What were PhaseRx earnings last quarter?▼
PZRXQ earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PhaseRx revenue for the last year?▼
PhaseRx revenue for the last year amounts to 0 USD.
What is PhaseRx net income for the last year?▼
PZRXQ net income for the last year is -40.27M USD.
How many employees does PhaseRx have?▼
As of April 17, 2026, the company has 10 employees.
In which sector is PhaseRx located?▼
PhaseRx operates in the Health & Wellness sector.
When did PhaseRx complete a stock split?▼
PhaseRx has not had any recent stock splits.
Where is PhaseRx headquartered?▼
PhaseRx is headquartered in Seattle, United States.